Search results for "Angina"

showing 10 items of 211 documents

BIOMARKERS OF CORONARY MICROVASCULAR DYSFUNCTION IN PATIENTS WITH MICROVASCULAR ANGINA: A NARRATIVE REVIEW

2021

The current gold standard for diagnosis of coronary microvascular dysfunction (CMD) in the absence of myocardial diseases, whose clinical manifestation is microvascular angina (MVA), is reactivity testing using adenosine or acetylcholine during coronary angiography. This invasive test can be difficult to perform, expensive, and harmful. The identification of easily obtainable blood biomarkers which reflect the pathophysiology of CMD, characterized by high reliability, precision, accuracy, and accessibility may reduce risks and costs related to invasive procedures and even facilitate the screening and diagnosis of CMD. In this review, we summarized the results of several studies that have i…

0301 basic medicineCoronary angiographymedicine.medical_specialtyClinical manifestationCoronary Artery Disease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemicrovascular dysfunction (CMD) oxidative stress inflammation endothelial dysfunction microvascular angina (MVA)Internal medicineCoronary CirculationMedicineHumansIn patientEndothelial dysfunctionMicrovascular Anginabusiness.industryMicrocirculationMicrovascular anginaReproducibility of ResultsGold standard (test)medicine.disease030104 developmental biologyCardiologyNarrative reviewCardiology and Cardiovascular MedicinebusinessBiomarkersReactivity Testing
researchProduct

Inorganic nitrite and nitrate in cardiovascular therapy: A better alternative to organic nitrates as nitric oxide donors?

2017

In 1867 the organic nitrite, amyl nitrite, was introduced as a therapeutic agent in the treatment of angina pectoris and was later substituted by the organic nitrate nitroglycerin (NTG). Despite having a highly potent vasodilator capacity in veins>coronary arteries>arterioles, the vasodilator effects NTG are rapidly attenuated by the development of nitrate tolerance. We and others established that NTG treatment stimulates the production of reactive oxygen species such as superoxide and peroxynitrite with subsequent marked attenuation of the NTG vasodilator potency. The nitrite anion (NO2-) has more recently been characterized to possess novel pharmacotherapeutic actions such as modulation o…

0301 basic medicinePhysiologyVasodilator AgentsVasodilation030204 cardiovascular system & hematologyPharmacologyNitric OxideCardiovascular SystemNitric oxideAngina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNitratemedicineAnimalsHumansNitric Oxide DonorsNitriteNitritesPharmacologyNitratesSuperoxidemedicine.diseaseVasodilation030104 developmental biologychemistryBiochemistryCardiovascular DiseasesMolecular MedicineAmyl nitritePeroxynitriteSignal Transductionmedicine.drugVascular Pharmacology
researchProduct

Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Met…

2016

Background Medications aimed at inhibiting the renin–angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. Methods and Findings Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. T…

ACE inhibitorsMyocardial InfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE inhibitor therapyBiochemistryRenin-Angiotensin SystemAnginachemistry.chemical_compoundEndocrinologyMathematical and Statistical Techniques0302 clinical medicineReninMedicine and Health SciencesSecondary Prevention030212 general & internal medicineMyocardial infarctionDiureticsStrokePharmaceuticsRDrugsEnzyme inhibitorsCardiovascular therapyGeneral Medicine3. Good healthHospitalizationStrokeNephrologyCardiovascular DiseasesPhysical SciencesCardiologyMedicineDrug therapyStatistics (Mathematics)Research Articlemedicine.drugAdultmedicine.medical_specialtyEndocrine DisordersCardiologyResearch and Analysis MethodsAngina PectorisDiabetes ComplicationsAngiotensin Receptor Antagonists03 medical and health sciencesDiabetes mellitusInternal medicineRenal DiseasesDiabetes MellitusmedicineHumansStatistical MethodsRenal Insufficiency ChronicPharmacologyHeart FailureCreatinineBiology and life sciencesbusiness.industryOdds ratiomedicine.diseasechemistryMetabolic DisordersHeart failuresistema cardiovascularACE inhibitorEnzymologyKidney Failure ChronicbusinessMathematicsMeta-AnalysisPLOS Medicine
researchProduct

Risk stratification in non-ST elevation acute coronary syndromes

2005

Abstract Introduction: In acute coronary syndromes, myocardial damage markers and acute-phase reactants predict adverse cardiac events. The aim of this study was to define the fitted prognostic value of the most widely used variables of necrosis and inflammation as well as of homocysteine. Methods and results: Troponin I, high-sensitivity C-reactive protein, fibrinogen and homocysteine were measured in 515 consecutive patients admitted to our institution for non-ST elevation acute coronary syndrome. The risk for major events (death or nonfatal myocardial infarction) through 6 months of follow-up was analysed. In the univariate analysis, all markers were related to major events ( p 11 mg/l (…

Acute coronary syndromemedicine.medical_specialtyHomocysteinebiologyUnstable anginabusiness.industryST elevationC-reactive proteinmedicine.diseaseTroponinchemistry.chemical_compoundchemistryInternal medicineTroponin Imedicinebiology.proteinCardiologyMyocardial infarctionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

2014

Introduction Particularly in the setting of acute coronary syndromes, the interplay between vascular and platelet function has been postulated to have direct clinical implications. The present trial is designed to test the effect of clopidogrel, prasugrel and ticagrelor on multiple parameters of vascular function, platelet aggregation, oxidative and inflammatory stress before and up to 4 weeks after coronary artery stenting. Methods and analysis The study is designed as a three-arm, parallel design, randomised, investigator-blinded study. Patients with unstable angina or non-ST elevation myocardial infarction undergoing coronary intervention with a drug-eluting stent will be randomised to r…

Acute coronary syndromemedicine.medical_specialtyPrasugrel HydrochloridePrasugrelUnstable anginabusiness.industryGeneral MedicineClopidogrelmedicine.diseaseInternal medicinemedicineCardiologyPlatelet aggregation inhibitorTiclopidinebusinessTicagrelormedicine.drugBMJ Open
researchProduct

Valor pronóstico de la troponina T en pacientes hospitalizados con angina o infarto sin elevación del segmento ST

2003

Introduction and objectives. Cardiac troponins are highly specific and sensitive for detecting minimal myocardial damage. The aim of our study was to determine the prognostic value of troponinT levels in patients hospitalized for suspected angina or myocardial infarction without STsegment elevation. Patients and method. We recorded the frequency of death, acute myocardial infarction, heart failure, or need for coronary revascularization in the three months after the onset of symptoms in 346 consecutive patients admitted for suspected acute coronary syndrome, excluding those who developed myocardial infarction with persistent ST-segment elevation. Results. Serum troponin T levels were ≥ 0.1 …

Acute coronary syndromemedicine.medical_specialtyTroponin TUnstable anginabusiness.industrymedicine.diseaseChest painAnginaInternal medicineHeart failuremedicineCardiologyMyocardial infarction diagnosisMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología
researchProduct

Cystatin C levels are decreased in acute myocardial infarction: Effect of cystatin C G73A gene polymorphism on plasma levels

2005

Background: Cystatin C is the most abundant protease inhibitor in the plasma. Low plasma levels have been found in patients with aortic aneurysms and they seem correlated with the extension of the aortic lesions in early aneurysms detected by ultrasonography. Methods: In this study, plasma levels of cystatin C have been investigated in patients with acute myocardial infarction (AMI), unstable angina and controls. The effect on plasma levels of the G73A polymorphism of the CST3 gene has been also evaluated. Results: Patients with acute myocardial infarction showed significantly lower levels of cystatin C compared to unstable angina and controls, but levels were nearly normal in a week after …

Acute myocardial infarctionCystatin CCoronary artery diseaseUnstable angina
researchProduct

The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean pop…

2006

The aim of this study was to evaluate the cardiovascular (CV) risk due to the metabolic syndrome in a 15-year prospective study of a Sicilian population. In the Mediterranean area obesity is highly prevalent, but epidemiological data on the metabolic syndrome are limited. Methods and results: Among the 1351 subjects enrolled in the “Ventimiglia di Sicilia” epidemiological project, we selected 687 subjects between 35 and 75 years of age; baseline parameters were assessed and subjects have been followed for 15 years recording CV events, total and cardiovascular mortality. The metabolic syndrome was defined according to both the Adult Treatment Panel III and the International Diabetes Federati…

AdultBlood GlucoseMalemedicine.medical_specialtyEpidemiologyPopulationMyocardial InfarctionCoronary Artery DiseaseKaplan-Meier EstimateAngina PectorisCoronary artery diseasePredictive Value of TestsRisk FactorsInternal medicineDiabetes mellitusEpidemiologyGlucose IntolerancemedicineDiabetes MellitusPrevalenceHumansObesityProspective StudieseducationProspective cohort studySicilyAgedMetabolic Syndromeeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceFastingMiddle Agedmedicine.diseaseCardiovascular diseaseObesityStrokeEndocrinologyCardiovascular DiseasesFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesAtherosclerosis
researchProduct

Impairment of the extrusion transporter for asymmetric dimethyl-L-arginine: a novel mechanism underlying vasospastic angina.

2012

Abstract A 37-year old male patient presented with frequent angina attacks (up to 40/day) largely resistant to classical vasodilator therapy. The patient showed severe coronary and peripheral endothelial dysfunction, increased platelet aggregation and increased platelet-derived superoxide production. The endothelial nitric oxide synthase (eNOS)-inhibitor N G -nitro- l -arginine methyl ester (L-NAME) reduced superoxide formation in platelets identifying “uncoupled” eNOS as a superoxide source. Oral l -arginine normalized coronary and peripheral endothelial dysfunction and reduced platelet aggregation and eNOS-derived superoxide production. Plasma concentrations of the endogenous NOS inhibito…

AdultBlood PlateletsMalemedicine.medical_specialtyArginineNitric Oxide Synthase Type IIIBiophysicsCoronary VasospasmVasodilationArginineBiochemistryPeripheral blood mononuclear cellAngina Pectorischemistry.chemical_compoundEnosSuperoxidesInternal medicinemedicineHumansPlateletEndothelial dysfunctionEnzyme InhibitorsMolecular BiologybiologyChemistrySuperoxideCell Biologymedicine.diseasebiology.organism_classificationEndocrinologyNG-Nitroarginine Methyl EsterEndothelium VascularIntracellularBiochemical and biophysical research communications
researchProduct

Sublingual administration of captopril in patients with acute myocardial ischemia.

1991

Summary: To investigate the anti-ischemic capability of the angiotensin-converting enzyme inhibitor captopril, 10 patients with acute myocardial ischemia (angina pectoris >1 h, ST-segment depression ±0.1 mV, no rise in creatine phosphokinase) received 25 mg captopril sublingually after being treated with an intravenous infusion of nitroglycerin (3 mg/h) and heparin (1200 IU/h) for 1 hour. A control group of 10 patients received placebo instead of captopril. Results showed a decrease of the initial ST-segment depression from 0.25±0.04 to 0.2±0.03 mV (p>0.01) with nitroglycerin for the captopril group and from 0.26±0.05 to 0.21±0.05 mV (p>0.01) for the control group. An additional decrease to…

AdultMaleCaptoprilAdministration SublingualCoronary DiseasePlaceboSublingual administrationAngina PectorisAnginaElectrocardiographyNitroglycerinHeart ratemedicineHumanscardiovascular diseasesMyocardial infarctionCreatine KinaseClinical Trials as Topicbiologybusiness.industryHemodynamicsCaptoprilGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureAnesthesiaAcute DiseaseVascular resistancebiology.proteinCreatine kinaseDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical cardiology
researchProduct